Filtered By:
Condition: Diabetes
Management: Hospitals

This page shows you your search results in order of relevance. This is page number 12.

Order by Relevance | Date

Total 528 results found since Jan 2013.

Measuring Ambulation, Motor, and Behavioral Outcomes with Poststroke Fluoxetine in Tanzania: The Phase II MAMBO Trial
Am J Trop Med Hyg. 2021 Dec 6:tpmd210653. doi: 10.4269/ajtmh.21-0653. Online ahead of print.ABSTRACTWe test the safety of fluoxetine postischemic stroke in sub-Saharan Africa. Adults with acute ischemic stroke, seen <14 days since new-onset motor deficits, were enrolled from November 2019 to October 2020 in a single-arm, open-label phase II trial of daily fluoxetine 20 mg for 90 days at Muhimbili National Hospital, Dar es Salaam, Tanzania. The primary outcome was safety with secondary outcomes of medication adherence and tolerability. About 34 patients were enrolled (11 were female; mean age 52.2 years, 65% < 60 year...
Source: Am J Trop Med Hyg - December 6, 2021 Category: Infectious Diseases Authors: Farrah Mateen Emmanuel Massawe Notburga Mworia Seif Ismail Dylan Rice Andre Vogel Boniface Kapina Novath Mukyanuzi Deus Buma Jef Gluckstein Michael Wasserman Susan Fasoli Faraja Chiwanga Kigocha Okeng'o Source Type: research

There is a Decreased Risk of Hospitalization from Heart Failure in Type II Diabetics Initiated on a SGLT2 Inhibitor When Compared to a GLP-1 Receptor Agonist
Dr. Huang Clinical question: Determine the cardiovascular risk outcome in type II diabetic patients initiated on an sodium-glucose cotransporter-2 (SGLT2)  inhibitor versus a glucagon-like peptide-1 (GLP-1) receptor agonist. Background: Various studies have suggested that several SGLT2 inhibitors and GLP-1 receptor agonists may improve cardiac outcomes—myocardial infarction, stroke, hospitalization for heart failure, and cardiovascular death. Current guidelines recommend using either an SGLT2 inhibitor or GLP-1 receptor agonist for patients with type II diabetes and cardiovascular disease. However, there has been no st...
Source: The Hospitalist - September 1, 2022 Category: Hospital Management Authors: Ronda Whitaker Tags: Diabetes Heart Failure In the Literature Source Type: research

Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions.
Authors: Schoepf D, Uppal H, Potluri R, Heun R Abstract Schizophrenia is a major psychotic disorder with significant comorbidity and mortality. Patients with schizophrenia are said to suffer more type-2 diabetes mellitus (T2DM) and diabetogenic complications. However, there is little consistent evidence that comorbidity with physical diseases leads to excess mortality in schizophrenic patients. Consequently, we investigated whether the burden of physical comorbidity and its relevance on hospital mortality differed between patients with and without schizophrenia in a 12-year follow-up in general hospital admissions....
Source: European Archives of Psychiatry and Clinical Neuroscience - August 15, 2013 Category: Psychiatry Tags: Eur Arch Psychiatry Clin Neurosci Source Type: research

Saturated fat link with heart disease questioned
This article is one doctor's opinion based on his own knowledge, research and experience. However, it is fair to say there is an ongoing debate about how far cholesterol is a risk factor for heart disease, especially in people who are otherwise healthy. There is also a similar debate about the use of statins in people who have no evidence of cardiovascular disease. This is alongside ongoing research into the components of LDL and the different types of lipoproteins known to increase risk the most. None of this relevant new evidence is covered by the news reporting.   What should you eat? There is no need to change curren...
Source: NHS News Feed - October 23, 2013 Category: Consumer Health News Tags: Heart/lungs Food/diet QA articles Source Type: news

Infective endocarditis: old problem, new guidelines and still much to learn
Despite major advances in treating valvular heart disease, the in-hospital mortality (15–20%) and 1-year mortality (~=40%) for infective endocarditis (IE) has not improved even with modern antibiotics and surgical therapy. Further, stroke (17%), embolisation other than stroke (23%), heart failure (HF) (32%) and other complications remain common; therefore, all precautions to help prevent IE should be employed where indicated. In underdeveloped countries, IE is most often associated with rheumatic heart disease. In developed countries, IE is increasingly associated with prosthetic valves and intracardiac devices, with...
Source: Heart - June 9, 2014 Category: Cardiology Authors: Erwin, J. P., Otto, C. M. Tags: Drugs: cardiovascular system, Echocardiography, Clinical diagnostic tests, Epidemiology, Diabetes, Metabolic disorders Editorials Source Type: research

The value of CHADS score in predicting new-onset atrial fibrillation in Chinese patients with acute myocardial infarction
Previous studies have shown that new-onset atrial fibrillation (AF) in the setting of acute myocardial infarction (AMI) was associated with increased in-hospital and long term mortality [1,2]. Therefore, it was crucial to recognize the patients with AMI who were on the increased risk for developing new-onset AF. CHADS2 score (congestive heart failure, hypertension, age≥75years, diabetes and previous stroke or transient ischemic attack) was a very useful and convenient scoring system, which was widely used for the stroke risk stratification in the patients with non-valvular AF [3].
Source: International Journal of Cardiology - August 5, 2014 Category: Cardiology Authors: Xiaowei Zhang, Guangping Li, Zhiqiang Zhao, Yanmin Xu, Tong Liu Source Type: research